Type 2 Diabetes - Kailera K9531-3104

Type 2 Diabetes – Kailera K9531-3104

Participating in a clinical trial with Profound means making a real difference in the lives of others facing similar health challenges.

The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to placebo on:

Key Inclusion Criteria:

Diagnosis of type 2 diabetes mellitus (T2DM).
Receiving stable therapy for T2DM for 3 months prior to Screening. This includes diet/exercise alone and any oral medication for T2DM treatment except for glucagon-like peptide-1 receptor (GLP-1R) agonist, GLP-1R/glucose-dependent insulinotropic polypeptide receptor (GIPR) dual agonist, or dipeptidyl peptidase-4 (DPP-4) inhibitors.
BMI ≥27 kg/m^2.
History of at least 1 self-reported unsuccessful effort to lose weight with diet and exercise within the prior 6 months.
Other criteria may apply.

Complete the form and our team will reach out soon to help determine your eligibility.

View Study on ClinicalTrials.gov

Trial Interest Form

I am a...

First Name(Required)

Last Name(Required)

Location(Required)

Phone(Required)

Email(Required)

Gender

Conditions

Race

Contact Preference

How did you hear about us?

Other (Please specify)

This field is hidden when viewing the form

Trial (Origination Page)

This field is hidden when viewing the form

UTM Source

This field is hidden when viewing the form

UTM Medium

This field is hidden when viewing the form

UTM Campaign

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

Phone(Required)

Zip Code(Required)

What is the best way to contact you?(Required)

Comments(Required)

Please let us know what's on your mind. Have a question for us? Ask away.

This field is hidden when viewing the form

Origination Page

Type 2 Diabetes – Kailera K9531-3104